cyclic octapeptides+doxil conjugate (BiOrion Technologies)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namecyclic octapeptides+doxil conjugate (BiOrion Technologies)
Drug Alias NamePDGFR-beta modulator (BiOrion Technologies)BOT-162
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionPlatelet-derived growth factor receptor beta modulatorsTopoisomerase II inhibitorsVirus DNA polymerase inhibitors +[4] 
TargetsTopoisomerase IIPlatelet-derived growth factor receptor betaDNA +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiorion Technologies
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiorion Technologies
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A